Streetbeat News

GUTS

Fractyl Health Inc.

Industry

Surgical and Medical Instrument Manufacturing

Open

1.29

Mkt cap

62M

Volume

265K

High

1.30

P/E Ratio

-0.78

52-wk high

8.37

Low

1.23

Div yield

N/A

52-wk low

1.16

Fractyl Health, Inc. (NASDAQ:GUTS) held its Q4 2024 earnings call, discussing financial results and business updates. Key participants included CEO Harith Rajagopalan and CFO Lisa Davidson.

Portfolio Pulse from

March 04, 2025 | 1:15 am

Fractyl Health released its Q4 and full-year 2024 financial results, highlighting strong demand for its REMAIN-1 study, which addresses weight maintenance post-GLP-1 withdrawal. Midpoint data is expected in Q2 2025, with full enrollment by summer 2025.

Portfolio Pulse from

March 03, 2025 | 9:30 pm

Fractyl Health, Inc. (Nasdaq: GUTS) will announce its Q4 and full year 2024 financial results and provide business updates on March 3, 2025.

Portfolio Pulse from

February 24, 2025 | 12:15 pm

Fractyl Health, Inc. (GUTS) has experienced a significant decline of 19.55% over the past four weeks. However, the stock is now in oversold territory, and Wall Street analysts are showing strong agreement in raising earnings estimates, which could lead to a trend reversal.

Portfolio Pulse from

February 12, 2025 | 4:00 pm

Fractyl Health, Inc. (Nasdaq: GUTS) will participate in two upcoming investor conferences, with CEO Harith Rajagopalan presenting. The company focuses on metabolic therapeutics for obesity and Type 2 Diabetes.

Portfolio Pulse from

November 26, 2024 | 12:15 pm

Fractyl Health, Inc. (NASDAQ:GUTS) held its Q3 2024 earnings call, discussing financial results and business updates. Key participants included CEO Harith Rajagopalan and CFO Lisa Davidson.

Portfolio Pulse from

November 15, 2024 | 4:15 am

Fractyl Health, Inc. (Nasdaq: GUTS) reported its Q3 2024 financial results and provided updates on its weight maintenance and diabetes treatment studies. Key data releases are expected in late 2024 and mid-2025.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

Fractyl Health's stock is rising following the announcement that it will present new data on its Revita and Rejuva platforms at ObesityWeek 2024.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 12:28 pm

Fractyl Health is set to present data on weight maintenance from its Revita and Rejuva platforms at ObesityWeek 2024 on November 3 and 5. This presentation could provide insights into the effectiveness of their platforms in managing obesity.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 11:04 am

The article reports on the after-market session movements of various healthcare stocks. Notable gainers include Carmell (CTCX) with a 31% increase and Processa Pharma (PCSA) with a 30.07% rise. Among the losers, Soligenix (SNGX) saw an 8.6% decline, and Inspire Veterinary (IVP) fell by 6.34%.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.